模式识别分子及其受体在肺炎支原体感染中的作用
被引量:1
Function of pattern recognition molecules and receptors in Mycoplasma pneumoniae infections
摘要
肺炎支原体(MP)是一种人类致病原,可引起呼吸系统的感染,且与支气管哮喘的发病密切相关,并可导致广泛多系统、多器官的肺外并发症。但到目前为止,MP感染的发病机制仍不十分清楚,近来模式识别分子和受体在MP感染中的作用日益受到重视。该文就模式识别分子(如肺表面活性物质相关蛋白A、D)及其受体(如Toll样受体)在MP感染中的作用作一综述。
出处
《国际儿科学杂志》
2009年第1期17-19,共3页
International Journal of Pediatrics
参考文献21
-
1Vervloet LA,Marguet C,Camargos PA.Infection by Mycoplasma pneumoniae and its importance as an etiological agent in childhood community-acquired pneumonias. Braz J Infect Dis,2007,11(5) :507-514.
-
2Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev, 2004,17(4) : 697-728.
-
3Nisar N, Guleria R, Kumar S, et al. Mycoplasma pneumoniae and its role in asthma. Postgrad Med J,2007,93(976) : 100-104.
-
4China H, Pattanajitvilai S,Mitsuzawa H, et al.Pulmonary surfactant proteins A and D recognize lipid ligands on Mycoplasma pneumoniae and markedly augment the innate immune response to the organism. Chest,2003, 123 3 Suppl: 426S.
-
5Chu HW,Jeyaseelan S,Rino JG,et al.TLR2 signaling is critical for Mycoplasmapnetunoniae-induced airway mucin expression. J Immunol, 2005,74 (9) : 5713-5719.
-
6Crouch E, Wright JR. Suffactant proteins a and d and pulmonary host defense. Annu Rev Physiol, 2001,63 : 521-554.
-
7Khubchandani KR, Snyder JM. Surfactant protein A (SP-A) : the alveolus and beyond. Faseb J, 2001,15 ( 1 ) : 59-69.
-
8Kannan TR, Provenzano D, Wright JR, et al.Identification and cbaracterization of human surfactant protein A binding protein of Mycoplasma pneumoniae. Infect Immun, 2005,73 (5) : 2828-2834.
-
9Piboonpocanun S, Chiba H, Mitsuzawa H, et al. Surfaetant protein A binds Myeoplasma pneumoniae with high affinity and attenuates its growth by recognition of disaturated phosphatidylglycerols. J Biol Chem, 2005, 280 (1):9-17.
-
10Kannan TR, Baseman JB. ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens.Proc Nad Acad Sci U S A,2006,103(17):6724-6729.
同被引文献6
-
1刘世英,赫宝兰,任亦欣.支原体感染与哮喘发病关系的研究[J].中华儿科杂志,1996,34(2):137-138. 被引量:45
-
2韩连书,戴家熊.糖皮质激素防治儿童哮喘进展(讲座)[J].临床儿科杂志,1996,14(5):347-349. 被引量:21
-
3Daian CM, Wolff AH, Bielory L, et al. The role of atypical organisms in asthma [J]. Allergy Asthma Proc, 2000, 21 (2) :107-111.
-
4Koh YY,Chae SA,Min KU. Cough variant asthma is associated with a higher wheezing threshold than classic asthma[J]. Clin Exp Allergy,1993,23, (8) :696-701.
-
5刘焕(综述),何庆南(审校).儿童慢性咳嗽的病因分析及进展[J].国际儿科学杂志,2009,36(1):22-24. 被引量:6
-
6王晓芳,洪建国.肺炎支原体与哮喘的关系[J].中国实用儿科杂志,2009,24(8):648-650. 被引量:39
-
1黄国盛,唐上英,廖燕,张俊玲.肺表面活性物质治疗新生儿重症胎粪吸入综合征的临床研究[J].中国新生儿科杂志,2008,23(1):8-11. 被引量:22
-
2马玉龙,郭康,邓保国,温小军.克拉霉素联合地塞米松对肺炎支原体感染小鼠干扰素-γ、白介素-4表达的影响[J].贵阳医学院学报,2014,39(4):552-555. 被引量:1
-
3赵俊玲.小儿肺炎支原体感染行个性化护理的效果研究[J].临床合理用药杂志,2014,7(18):118-119. 被引量:5
-
4张兆兰,李爱芳,任秀丽.克拉霉素分散片治疗轻症小儿支原体肺炎疗效分析[J].临床荟萃,2013,28(6):687-688.
-
5向四国,胡忠金,仰霞.成人肺炎支原体肺炎84例临床分析[J].淮海医药,2006,24(1):41-41. 被引量:3
-
6郝嘉,肖颖彬.肺表面活性物质相关蛋白A研究现状[J].中国危重病急救医学,2000,12(1):60-61. 被引量:12
-
7严兴科,杨波,高洋.肺表面活性物质相关蛋白A与哮喘[J].Journal of US-China Medical Science,2007,4(8):35-38. 被引量:1
-
8阎志新,张西凯,张有起,钱慧莉.改良法推注肺表面活性物质神经系统后遗症观察[J].中国误诊学杂志,2012,12(9):2039-2039. 被引量:2
-
9杨昌慧.肺泡表面活性物质联合NCPAP治疗新生儿呼吸窘迫综合征27例的护理[J].中国误诊学杂志,2010,10(5):1156-1157. 被引量:2
-
10李琛,芦红伟.早期应用注射用牛肺表面活性剂联合机械通气治疗早产儿呼吸窘迫综合征临床分析[J].临床荟萃,2011,26(4):338-339. 被引量:15